DLL3 and neoplasm: Public data from the IMpower133 trial further validated the chemo‐resistant role of the MYC‐Notch‐non‐NE axis and highlighted the importance of the inhibitory Notch ligand, DLL3, in predicting response to chemo‐immunotherapy and promoting an immune‐supportive tumor phenotype.